Definition of Advanced Cell Therapy Trials:
We define Advanced Cell Therapy as all therapies in which cells are more than minimally manipulated, and/or their action is not homologous.
Our definition is similar to the European Medicines Agency (EMA) definition of Advanced Therapy Medicinal Product (ATMP): “Medicinal product for human use that is a gene therapy medicinal product, a somatic cell therapy medicinal product or tissue engineered product” (EMA ATMP Reg. No. 1394/2007)
The definition of Advanced Cell Therapy overlaps with, but is not the same as, Regenerative Medicine, which is defined as therapy that "replaces or regenerates human cells, tissue or organs, to restore or establish normal function" (Mason & Dunnil 2008)
Advanced Cell Therapy encompasses Regenerative Medicine with cells, and in addition includes Cellular Immunotherapy, Gene Therapy that is delivered by cells, and Tissue Engineering that is seeded or administered with cells.
Note that Advanced Cell Therapy does not include Hematopoietic Stem Cell Transplants (HSCT), unless the cells are more than minimally manipulated before they are administered. Advanced Cell Therapy does not include Gene Therapy or Tissue Engineering that does not employ cells.
Please bear in mind that the other compilations in our comparison table each have their own selection criteria for compiling trials.
| Acronym | Definition |
| AE | Adverse Events |
| ALDHbr cells | Aldehyde Dehydrogenase Bright Cells |
| ALL | Acute Lymphoblastic Leukemia |
| Allo | Allogeneic |
| AML | Acute Myeloid Leukemia |
| APH | Apheresis (leukapheresis) |
| AT | Adipose Tissue |
| Auto | Autologous |
| BM | Bone Marrow |
| BMAC | Bone Marrow Aspirate Concentrate |
| CAR | Chimeric Antigen Receptors |
| CB | Cord Blood |
| CIK | Cytokine-induced Killer Cells |
| CLL | Chronic Lymphocytic Leukemia |
| CMV | Cytomegalovirus |
| CR | Complete Remission |
| CRS | Cytokine Release Syndrome |
| CTL | Cytotoxic T Lymphocytes |
| Cy | Cyclophosphamide |
| DC | Dendritic Cells |
| DLBCL | Diffuse Large B Cell Lymphoma |
| DLCL | Diffuse Large Cell Lymphoma |
| DLI | Donor Lymphocyte Infusion |
| DP | Dental Pulp |
| EPC | Endothelial Progenitor Cells |
| ESC | Embryonic Stem Cells |
| FCRx | Facilitating Cell Platform Technology (Hematopoietic Cells Bioengineered) |
| Flu | Fludarabine |
| hRPE-ESC | Human Retinal Pigmented Epithelial- Embryonic Stem Cells |
| HSC | Hematopoietic Stem Cells |
| HSCT | Hematopoietic Stem Cell Transplant |
| HSPC | Hematopoietic Stem Progenitor Cells |
| HuCNS-SC | Human Central Nervous System-Stem Cells |
| IV | intravenous |
| lenti- | lentiviral vector |
| MAPC | Multipotent Adult Progenitor Cells |
| MIL | Marrow Infiltrating Lymphocytes |
| MNC | Mononuclear Cells |
| MRD | Minimal Residual Disease |
| MSC | Mesenchymal Stem/Stromal Cells |
| NHL | Non-Hodgkins Lymphoma |
| NK | Natural Killer cells |
| NKT | Natural Killer T-Cell |
| ORR | Overall/Objective Response Rate |
| OS | Overall Survival |
| PB | Peripheral Blood |
| PD | Progressive Disease |
| PR | Partial Response |
| pedi- | Pediatric Patients |
| PFS | Progression-Free Survival |
| PLL | ProLymphocytic Leukemia |
| PTS | Patients |
| retro- | retroviral vector |
| Ritu | Rituximab |
| RPE-iPS | Retinal Pigmented Epithelial-induced Pluripotent Stem Cells |
| SD | Stable Disease |
| SLL | Small Lymphocytic Lymphoma |
| SVF | Stromal Vascular Fraction |
| TCR | T-Cell Receptor |
| TIL | Tumor-infiltrating lymphocytes |
| UC | Umbilical Cord |
| VST | Virus-Specific T-Cell |